Sanofi SA (SNY) is nearing a deal with private equity firm Clayton Dubilier & Rice (CD&R) for the sale of a controlling stake in Opella, its consumer health division. The proposed transaction, valued at €16 billion ($17.36 billion), signifies Sanofi’s focus on innovative pharmaceuticals and vaccines, while establishing Opella as a standalone player in the consumer healthcare market. The deal, expected to close in the second quarter of 2025, has been met with mixed reactions, highlighting the strategic and financial intricacies involved.